Entera Bio Ltd. (ENTX) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies using its proprietary N-Tab™ technology. The company's primary product candidates include EB613 (oral PTH for osteoporosis), EB612 (oral PTH for hypoparathyroidism), and a collaboration with OPKO Health for an oral GLP-1/Glucagon dual agonist (OPK-88006) for obesity and metabolic disorders.
Key Financial Metrics
| Metric (in thousands USD) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenues | $42 | $57 |
| Net Loss | $(5,223) | $(4,162) |
| Operating Loss | $(5,231) | $(4,227) |
| Research & Development Expenses | $2,643 | $1,821 |
| General & Administrative Expenses | $2,588 | $2,415 |
| Cash and Cash Equivalents | $10,858 | $9,056 |
| Restricted Cash | $8,015 | $0 |
| Total Cash & Restricted Cash | $18,954 | $9,134 |
| Accumulated Deficit | $(119,150) | $(108,548) |
Note: The filing does not provide specific gross margin percentages as gross profit was negligible ($0 for the six months ended June 30, 2025). The company has no debt obligations listed on the balance sheet other than operating lease liabilities.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased to $42,000 from $57,000 in the prior year period. The prior year revenue was derived from a research services agreement that was completed in Q1 2025, resulting in no revenue recognition for the three months ended June 30, 2025.
- Increased Operating Loss: Net loss increased by approximately 25% to $5.2 million for the six-month period, driven primarily by a 45% increase in R&D expenses.
- R&D Expense Growth: R&D expenses rose to $2.6 million (from $1.8 million), primarily due to increased consulting fees for regulatory meetings (Type A meeting for EB613) and optimization for the Phase 3 program, as well as costs related to the new OPKO collaboration.
- Liquidity Position: Total cash and restricted cash increased significantly to $18.9 million from $9.1 million. This increase is largely due to $8.0 million in restricted cash deposited into an escrow account to fund obligations under the new OPKO collaboration agreement.
- Equity Issuance: The company issued 3,685,226 shares to OPKO for $8.0 million and sold 2,700,000 shares under its ATM program for net proceeds of approximately $6.0 million.
Guidance, Outlook, and Risks
- EB613 Regulatory Milestone: In July 2025, the FDA agreed that the NDA filing for EB613 (osteoporosis) would be supported by a single 24-month Phase 3 study with Total Hip BMD as the primary endpoint. This allows the company to advance without waiting for the SABRE project qualification.
- OPKO Collaboration: A new agreement with OPKO was signed in March 2025 to develop an oral GLP-1/Glucagon dual agonist. Entera will fund 40% of development costs (using the escrowed $8.0 million) and retain 40% of proceeds, with an option to opt-out after Phase 1.
- Liquidity Outlook: Management believes current resources are sufficient to fund operations through the middle of Q3 2026. However, this runway excludes the capital required to initiate the Phase 3 program for EB613. Additional funding will be required for that specific milestone.
- Going Concern: The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern due to the history of losses and the need for additional capital to fund future clinical trials.
- Geopolitical Risks: The company highlights risks associated with the ongoing war in Israel (Hamas, Hezbollah, Iran). While current operations are largely unaffected, escalation could impact the workforce, supply chain, and ability to raise capital.
Investor Verification Checklist
- Phase 3 Funding Gap: Verify the specific capital requirements and timeline for initiating the EB613 Phase 3 trial, as current cash reserves do not cover this cost.
- Escrow Utilization: Monitor the drawdown of the $8.0 million restricted cash escrow account dedicated to the OPKO collaboration and the company's ability to fund its 40% share of costs.
- Geopolitical Impact: Assess the potential for escalation in the Middle East to disrupt the company's Israel-based research personnel and operations.
- ATM Program Capacity: Note the refresh of the ATM program allowing for the sale of an additional 30 million shares; monitor future dilution if the company relies on this for funding.
- Regulatory Pathway: Confirm the status of the FDA's qualification of BMD as a surrogate endpoint (SABRE project) and its potential impact on the NDA strategy.